West Pharmaceutical Services Inc (WST)

Debt-to-assets ratio

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Long-term debt US$ in thousands 72,800 152,100 205,600 206,100 206,700 207,200 207,800 208,300 208,800 209,900 251,800 252,300 252,900 253,400 253,900 254,400 255,000 195,100 196,000 195,500
Total assets US$ in thousands 3,829,500 3,754,700 3,669,600 3,723,600 3,616,800 3,316,800 3,361,700 3,294,700 3,313,800 3,142,600 2,933,500 2,739,700 2,793,800 2,582,800 2,392,300 2,246,500 2,341,400 2,174,000 2,123,200 2,036,200
Debt-to-assets ratio 0.02 0.04 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.07 0.09 0.09 0.09 0.10 0.11 0.11 0.11 0.09 0.09 0.10

December 31, 2023 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $72,800K ÷ $3,829,500K
= 0.02

The debt-to-assets ratio of West Pharmaceutical Services, Inc. has shown relatively stable levels over the past eight quarters. The ratio ranges between 0.05 to 0.08 during this period, indicating that the company maintains a conservative approach towards financing its operations using debt.

A lower debt-to-assets ratio, such as 0.05 or 0.06, suggests that a smaller portion of the company's assets is financed by debt, which can indicate a strong financial position and lower risk. On the other hand, a higher ratio, such as 0.08, might imply a higher level of debt relative to assets, potentially increasing financial risk.

Overall, the consistent but relatively low debt-to-assets ratio of West Pharmaceutical Services, Inc. suggests that the company has a prudent debt management strategy, balancing the use of debt financing with maintaining a solid asset base.


Peer comparison

Dec 31, 2023

Company name
Symbol
Debt-to-assets ratio
West Pharmaceutical Services Inc
WST
0.02
Carlisle Companies Incorporated
CSL
0.28